Golden Throat Holdings Group Company Limited logo

Golden Throat Holdings Group Company Limited

6896.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Latest quote

HK$2.245

−HK$0.01 · -0.44%

Aug 25, 4:08 PM HKT

6896.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Yong Zeng
Listed since
Jul 15, 2015
Employees
840

Market position

52-week range

Current HK$2.245

Open
HK$2.245
Previous close
HK$2.255
Volume
0
0× average
Average volume
415.76K
Average daily volume
Market cap
1.66B HKD
Beta
-0.16
Market reference 1
50-day average
HK$3.1157
-27.95% below average
200-day average
HK$3.295
-31.87% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.55B CNY
P/E (TTM)
5.83×
P/B (TTM)
1.03×
P/S (TTM)
1.51×
EV / EBITDA
4.6×
Earnings yield
12.40%
Free cash flow yield
3.85%
Dividend yield
15.14%

Profitability & efficiency

Gross margin
76.01%
Operating margin
32.10%
Net margin
26.63%
Return on equity
18.24%
Return on assets
10.97%
Return on invested capital
11.65%

Financial health

Debt / equity
0.42×
Current ratio
2.17×
Altman Z-score
3.94
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends81%60%39%18%Gross margin, FY2021: 70.41%Gross margin, FY2022: 72.67%Gross margin, FY2023: 72.57%Gross margin, FY2024: 75.46%Gross margin, FY2025: 76.01%Operating margin, FY2021: 23.24%Operating margin, FY2022: 35.98%Operating margin, FY2023: 36.35%Operating margin, FY2024: 32.80%Operating margin, FY2025: 32.10%Net margin, FY2021: 22.87%Net margin, FY2022: 28.35%Net margin, FY2023: 26.02%Net margin, FY2024: 26.89%Net margin, FY2025: 26.63%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 70.41%. Gross margin FY2022 72.67%. Gross margin FY2023 72.57%. Gross margin FY2024 75.46%. Gross margin FY2025 76.01%. Operating margin FY2021 23.24%. Operating margin FY2022 35.98%. Operating margin FY2023 36.35%. Operating margin FY2024 32.80%. Operating margin FY2025 32.10%. Net margin FY2021 22.87%. Net margin FY2022 28.35%. Net margin FY2023 26.02%. Net margin FY2024 26.89%. Net margin FY2025 26.63%.

Income trends

Revenue

943.26M CNY-20.40%

Operating income

302.79M CNY-22.11%

Net income

251.2M CNY-21.16%
Income trends across reported periods1.28B CNY885.8M CNY486.85M CNY87.91M CNYRevenue, FY2021: 820.54M CNYRevenue, FY2022: 992.01M CNYRevenue, FY2023: 961.38M CNYRevenue, FY2024: 1.19B CNYRevenue, FY2025: 943.26M CNYOperating income, FY2021: 190.66M CNYOperating income, FY2022: 356.9M CNYOperating income, FY2023: 349.49M CNYOperating income, FY2024: 388.73M CNYOperating income, FY2025: 302.79M CNYNet income, FY2021: 187.64M CNYNet income, FY2022: 281.22M CNYNet income, FY2023: 250.16M CNYNet income, FY2024: 318.63M CNYNet income, FY2025: 251.2M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 820.54M CNY. Revenue FY2022 992.01M CNY. Revenue FY2023 961.38M CNY. Revenue FY2024 1.19B CNY. Revenue FY2025 943.26M CNY. Operating income FY2021 190.66M CNY. Operating income FY2022 356.9M CNY. Operating income FY2023 349.49M CNY. Operating income FY2024 388.73M CNY. Operating income FY2025 302.79M CNY. Net income FY2021 187.64M CNY. Net income FY2022 281.22M CNY. Net income FY2023 250.16M CNY. Net income FY2024 318.63M CNY. Net income FY2025 251.2M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue943.26M CNY1.19B CNY961.38M CNY992.01M CNY820.54M CNY
Cost of goods sold226.25M CNY290.82M CNY263.66M CNY271.09M CNY242.81M CNY
Gross profit717.01M CNY894.18M CNY697.72M CNY720.92M CNY577.74M CNY
Research and development3.93M CNY32.42M CNY17.07M CNY6.42M CNY22.29M CNY
Selling, general, and administrative410.3M CNY473.04M CNY360.98M CNY357.6M CNY364.79M CNY
Operating expenses414.22M CNY505.46M CNY378.05M CNY364.02M CNY387.07M CNY
Interest income22.65M CNY25.25M CNY24.13M CNY16.55M CNY15.35M CNY
Interest expense14.38M CNY15.36M CNY10.7M CNY10.29M CNY7.98M CNY
Depreciation and amortization30.34M CNY36.43M CNY39.03M CNY38.64M CNY36.98M CNY
Operating income302.79M CNY388.73M CNY349.49M CNY356.9M CNY190.66M CNY
Net income251.2M CNY318.63M CNY250.16M CNY281.22M CNY187.64M CNY

Company facts updated Aug 25, 2026.

Earnings

Latest fiscal-year EPS
0.34
FY2025 · -20.93% year over year
Latest fiscal-year revenue
943.26M CNY
FY2025 · -20.40% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.450.380.30.23FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend1.22B1.08B929.88M784.1MFY21FY22FY23FY24FY25

6896.HK peers

ETFs holding 6896.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 6896.HK

research.disclaimer